These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 37075041)

  • 1. High risk oral contraceptive hormones do not directly enhance endothelial cell procoagulant activity in vitro.
    Bouck EG; Arvanitis M; Osburn WO; Sang Y; Reventun P; Ahmadzia HK; Smith NL; Lowenstein CJ; Wolberg AS
    PLoS One; 2023; 18(4):e0284333. PubMed ID: 37075041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on oral contraceptive-induced changes in blood coagulation and fibrinolysis and the estrogen effect on endothelial cells.
    Quehenberger P; Kapiotis S; Pärtan C; Schneider B; Wenzel R; Gaiger A; Speiser W
    Ann Hematol; 1993 Jul; 67(1):33-6. PubMed ID: 8392873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 micrograms and 30 micrograms ethinylestradiol.
    Winkler UH; Schindler AE; Endrikat J; Düsterberg B
    Contraception; 1996 Feb; 53(2):75-84. PubMed ID: 8838483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
    Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
    Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral contraceptives, sex steroid-induced antibodies and vascular thrombosis: results from 1318 cases.
    Beaumont V; Lemort N; Beaumont JL
    Eur Heart J; 1991 Nov; 12(11):1219-24. PubMed ID: 1782953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparanase procoagulant activity is elevated in women using oral contraceptives.
    Matan M; Axelman E; Brenner B; Nadir Y
    Hum Reprod; 2013 Sep; 28(9):2372-80. PubMed ID: 23800622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in haemostatic parameters during the menstrual cycle and subsequent use of drospirenone-containing oral contraceptives.
    Tchaikovski SN; Thomassen MC; Costa SD; Bremme K; Rosing J
    Thromb Res; 2014 Nov; 134(5):1032-7. PubMed ID: 25260941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
    Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
    Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
    Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined oral contraceptives containing estradiol valerate vs ethinylestradiol on coagulation: A randomized clinical trial.
    Haverinen AH; Luiro KM; Szanto T; Kangasniemi MH; Hiltunen L; Sainio S; Piltonen TT; Lassila R; Tapanainen JS; Heikinheimo O
    Acta Obstet Gynecol Scand; 2022 Oct; 101(10):1102-1111. PubMed ID: 35909329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smoking and use of oral contraceptives: impact on thrombotic diseases.
    Lidegaard O
    Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S357-63. PubMed ID: 10368521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.
    Rosing J; Middeldorp S; Curvers J; Christella M; Thomassen LG; Nicolaes GA; Meijers JC; Bouma BN; Büller HR; Prins MH; Tans G
    Lancet; 1999 Dec; 354(9195):2036-40. PubMed ID: 10636369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of chronic oral contraceptive steroids on theophylline disposition.
    Tornatore KM; Kanarkowski R; McCarthy TL; Gardner MJ; Yurchak AM; Jusko WJ
    Eur J Clin Pharmacol; 1982; 23(2):129-34. PubMed ID: 7140802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives.
    Norris LA; Bonnar J
    Br J Obstet Gynaecol; 1996 Mar; 103(3):261-7. PubMed ID: 8630312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters.
    Douxfils J; Klipping C; Duijkers I; Kinet V; Mawet M; Maillard C; Jost M; Rosing J; Foidart JM
    Contraception; 2020 Dec; 102(6):396-402. PubMed ID: 32956694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanical and Physical Behavior of Fibrin Clot Formation and Lysis in Combined Oral Contraceptive Users.
    Swanepoel AC; Bester J; de Lange-Loots Z
    Microsc Microanal; 2020 Oct; 26(5):1007-1013. PubMed ID: 32778190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian activity during regular oral contraceptive use.
    Crosignani PG; Testa G; Vegetti W; Parazzini F
    Contraception; 1996 Nov; 54(5):271-3. PubMed ID: 8934059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
    Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C
    Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drospirenone and non-fatal venous thromboembolism: is there a risk difference by dosage of ethinyl-estradiol?
    Bird ST; Delaney JA; Etminan M; Brophy JM; Hartzema AG
    J Thromb Haemost; 2013 Jun; 11(6):1059-68. PubMed ID: 23574590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.